Anna Zubrzycka‐Sienkiewicz

Peficitinib, a JAK Inhibitor, in the Treatment of Moderate‐to‐Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate

Alan Kivitz, Sergio Gutiérrez‐Ureña, Jeffrey E. Poiley et al. · Arthritis & Rheumatology · 2016 · 109 citations

Medicine, Pharmacology, Pharmacotherapy +15

Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease‐Modifying Antirheumatic Drugs in the Treatment of Moderate‐to‐Severe Rheumatoid Arthritis

Mark C. Genovese, Maria Greenwald, Christine E. Codding et al. · Arthritis & Rheumatology · 2017 · 90 citations

Medicine, Pharmacology, Pharmacotherapy +16

Efficacy and Safety of <scp>ABBV</scp>‐3373, a Novel Anti–Tumor Necrosis Factor Glucocorticoid Receptor Modulator Antibody–Drug Conjugate, in Adults with <scp>Moderate‐to‐Severe</scp> Rheumatoid Arthritis Despite Methotrexate Therapy: A Randomized, <scp>Double‐Blind</scp>, <scp>Active‐Controlled Proof‐of‐Concept</scp> Phase <scp>IIa</scp> Trial

Frank Buttgereit, Jacob Aelion, Bernadette Rojkovich et al. · Arthritis & Rheumatology · 2022 · 53 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study

Mark C. Genovese, Maria Greenwald, Sergio Gutiérrez‐Ureña et al. · Rheumatology and Therapy · 2019 · 15 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

OP0115 EFFICACY AND SAFETY OF ABBV-3373, A NOVEL ANTI-TNF GLUCOCORTICOID RECEPTOR MODULATOR ANTIBODY DRUG CONJUGATE, IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY: A PHASE 2A PROOF OF CONCEPT STUDY

Frank Buttgereit, Jacob Aelion, Bernadette Rojkovich et al. · Annals of the Rheumatic Diseases · 2021 · 12 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17